Clinical Trial Update: Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 translational study of MK-2206 in metastatic KRAS-wild-type, PIK3CA-mutated colorectal cancer was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Colon Cancer, Rectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-04-21